Moroctocog alfa efficacy in hemostasis management in a type hemophilia patients with elective arthroplasty

Abstract

Type A haemophilia is a hereditary coagulopathy caused by coagulation factor VIII deficiency as part of the rare, life-threatening and at-risk group of diseases that has been attributed over time a life-saving substitution treatment providing to patients diagnosed with this pathology a hope for life and quality of life similar to that of healthy population. However, substitution treatment is very expensive so that nowadays globally most patients cannot benefit from proper healthcare. The quality of healthcare is dependent on the socio-economic level of each country, being decisively influenced by the power of the National Hemophilia Organizations to generate solidarity and support of decision-makers of each country. One of the bleeding manifestations specific to haemophilia is haemarthrosis. Each haemorrhagic episode causes locally a disorder that predisposes to relapse, with the onset of the main chronic complication of this condition, haemophilic arthropathy. It has a slow evolution throughout the life of the patient and generates in time severe sequelae (ankyloses) that require total arthroplasty. Effective hemostasis is the essential element for performing this type of orthopaedic surgery, due to bleeding risk that is of vital nature, in this category of patients. In this sense, this study aims to underline the efficacy of Moroctocog alfa in the management of haemostasis in haemophiliac patients with total endoprosthesis indication, aimed to reduce joint pain and improve locomotor function.